While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in ...

For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

First-generation GLP-1 drugs like liraglutide (Saxenda) and exenatide (Byetta) were associated with a 41% lower risk of obesity-related cancers, compared with weight-loss surgery, researchers report ...

Discover how to boost your GLP-1 hormone levels naturally through diet and eating habits. Learn effective strategies to ...

In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

The researchers said they aren’t certain why these types of GLP-1 drugs have anticancer properties, but they said the lower risk could come from mechanisms such as reducing inflammation in the body.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.

but also capitalizes on the same biological mechanisms responsible for the success of popular weight-loss drugs. Semaglutide medications work by increasing the levels of a hormone called GLP-1 ...

Glucagon-like peptide-1 receptor agonists are tied to a reduction in alcohol intake in patients being treated for obesity.